Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

    Merck has previously stated that it will seek approval for the grazoprevir/elbasvir combination pill in the middle of the year. If approved by the end of the year or in early 2016 -- and there's probably little risk the therapy won't be approved -- Merck's dilemma will be finding a way to grab market share for a new hepatitis C therapy without any clinical or convenience advantages over the existing competition.

    09 April 2015 | The Street
  • ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations

    Through Positive Action, ViiV Healthcare has committed to invest £2 million per year to encourage MSM and transgender community-led interventions to reduce stigma and discrimination based on sexual orientation, gender identity/expression and/or HIV status. The first phase of the new programme will cover a period of two years.

    31 March 2015 | Viiv Healthcare press release
  • Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race

    Bristol-Myers Squibb took an intriguing approach to developing its hepatitis C drug, daclatasvir. Rather than focus its trials on the United States, the globe's biggest market for spending on medicine, it concentrated trials on Japan. That move allowed daclatasvir to carve out an early lead in Japan, but it also left investors wondering what the company's strategy for the drug in the United States would be -- particularly after the FDA balked at an initial application to approve the drug last fall. This week, Bristol-Myers shed some light on its strategy by announcing that it's resubmitting daclatasvir for approval in the U.S. as an adjunct treatment to be used alongside Gilead Sciences' (NASDAQ: GILD ) top-selling HCV drug Sovaldi in genotype 3 patients.

    18 March 2015 | Motley Fool
  • Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

    Sangamo's purportedly ground-breaking results in HIV with SB-728 do not stand up under close examination. SB-728 has not shown any indication that it can provide a "functional cure" for HIV, does not compare well to today's standard of care, and cannot find a partner. Sangamo refuses to conduct studies that rigorously assess whether their drugs work. This includes the inclusion of a control arm so assiduously avoided by Sangamo's management.

    10 March 2015 | Seeking Alpha
  • Here Is Why Gilead Sciences, Inc. Is Still Doing Better Than AbbVie Inc

    Based on the prescription data released by Symphony Health, the latest Bloomberg Intelligence (BI) analysis suggests that 95% of hepatitis C patients in the US are being administered with Gilead’s drugs, Harvoni and Sovaldi. On the other hand, AbbVie’s competing drug, Viekira Pak is only covering the remaining 4%.

    10 March 2015 | Bidness
  • $10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

    Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said Managing Director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.

    09 March 2015 | Bloomberg
  • EECA CAB positions in regards to Janssen, BMS, Gilead and ViiV policy

    EECA CAB (Community Advisory Board in Eastern Europe and Central Asia) has published its positions in regards to Janssen, BMS, ViiV and Gilead policy. The positions were developed on the results of the meetings with the companies during last year.

    09 March 2015 | EATG
  • Natco Pharma ties up with Gilead on hepatitis C drugs

    Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.

    04 March 2015 | Reuters
  • PrEP Access For HIV Prevention In Australia A Step Closer As Gilead Applies To TGA

    US pharmaceutical giant Gilead Sciences has begun the application process to have Truvada approved for PrEP in Australia, removing one of the most significant hurdles currently preventing access to the HIV-prevention drug and opening the door to affordable access.

    03 March 2015 | Star Observer
  • Gilead avoids billions in U.S. taxes on its $1,000-a-pill drug

    Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas.

    27 February 2015 | Chicago Tribune
More news


Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.